|
1
|
Ma X, Yang Y, Li HL, Zheng W, Gao J, Zhang
W, Yang G, Shu XO and Xiang YB: Dietary trace element intake and
liver cancer risk: Results from two population-based cohorts in
China. Int J Cancer. 140:1050–1059. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heidari-Soreshjani S, Asadi-Samani M, Yang
Q and Saeedi-Boroujeni A: Phytotherapy of nephrotoxicity-induced by
cancer drugs: An updated review. J Nephropathol. 6:254–263. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yood Ulcickas M, Bortolini M, Casso D,
Beck JG, Oliveria SA, Wells KE, Woodcroft KJ and Wang LI: Incidence
of liver injury among cancer patients receiving chemotherapy in an
integrated health system. Pharmacoepidemiol Drug Saf. 24:427–434.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen HH and Kuo MT: Role of glutathione in
the regulation of Cisplatin resistance in cancer chemotherapy. Met
Based Drugs. 2010:4309392010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen P, Hu MD, Deng XF and Li B: Genistein
reinforces the inhibitory effect of cisplatin on liver cancer
recurrence and metastasis after curative hepatectomy. Asian Pac J
Cancer Prev. 14:759–764. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cong Y, Wang L, Wang Z, He S, Zhou D, Jing
X and Huang Y: Enhancing therapeutic efficacy of cisplatin by
blocking DNA damage repair. ACS Med Chem Lett. 7:924–928. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li X, Xu H, Dai X, Zhu Z, Liu B and Lu X:
Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded
nanoparticles against liver cancer. Int J Nanomed. 7:5183–5190.
2012. View Article : Google Scholar
|
|
9
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q
and Kip KE: Metformin for liver cancer prevention in patients with
type 2 diabetes: A systematic review and meta-analysis. J Clin
Endocrinol Metab. 97:2347–2353. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ko EM, Walter P, Jackson A, Clark L,
Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig
PA, et al: Metformin is associated with improved survival in
endometrial cancer. Gynecol Oncol. 132:438–442. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wheaton WW, Weinberg SE, Hamanaka RB,
Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu GM,
Budigner GS, et al: Metformin inhibits mitochondrial complex I of
cancer cells to reduce tumorigenesis. eLife. 3:e022422014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li L, Han R, Xiao H, Lin C, Wang Y, Liu H,
Li K, Chen H, Sun F, Yang Z, et al: Metformin sensitizes
EGFR-TKI-resistant human lung cancer cells in vitro and in vivo
through inhibition of IL-6 signaling and EMT reversal. Clin Cancer
Res. 20:2714–2726. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu G, Fang W, Xia T, Chen Y, Gao Y, Jiao
X, Huang S, Wang J, Li Z and Xie K: Metformin potentiates rapamycin
and cisplatin in gastric cancer in mice. Oncotarget. 6:12748–12762.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu X, Chhipa RR, Pooya S, Wortman M,
Yachyshin S, Chow LM, Kumar A, Zhou X, Sun Y, Quinn B, et al:
Discrete mechanisms of mTOR and cell cycle regulation by AMPK
agonists independent of AMPK. Proc Natl Acad Sci USA. 111:pp.
435–444. 2014, View Article : Google Scholar
|
|
16
|
Vilà L, Roglans N, Perna V, Sánchez RM,
Vázquez-Carrera M, Alegret M and Laguna JC: Liver AMP/ATP ratio and
fructokinase expression are related to gender differences in AMPK
activity and glucose intolerance in rats ingesting liquid fructose.
J Nutr Biochem. 22:741–751. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hadad SM, Hardie DG, Appleyard V and
Thompson AM: Effects of metformin on breast cancer cell
proliferation, the AMPK pathway and the cell cycle. Clin Transl
Oncol. 16:746–752. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi WY, Xiao D, Wang L, Dong LH, Yan ZX,
Shen ZX, Chen SJ, Chen Y and Zhao WL: Therapeutic metformin/AMPK
activation blocked lymphoma cell growth via inhibition of mTOR
pathway and induction of autophagy. Cell Death Dis. 3:e2752012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Honjo S, Ajani JA, Scott AW, Chen Q,
Skinner HD, Stroehlein J, Johnson RL and Song S: Metformin
sensitizes chemotherapy by targeting cancer stem cells and the mTOR
pathway in esophageal cancer. Int J Oncol. 45:567–574. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Obara A, Fujita Y, Abudukadier A,
Fukushima T, Oguri Y, Ogura M, Harashima S, Hosokawa M and Inagaki
N: DEPTOR-related mTOR suppression is involved in metformin's
anti-cancer action in human liver cancer cells. Biochem Biophys Res
Commun. 460:1047–1052. 2015. View Article : Google Scholar : PubMed/NCBI
|
